Open Access
Stem Cell Tra nsplantation for Non - Hodgkin 's Lymphoma
David Wrench,John G. Gribben +1 more
- 01 Jan 2008
2
TL;DR: Although this approach has a relatively low toxicity compared with allogeneic HSCT (allo-HSCT), there is a persistent risk of tumor cells being present within the harvest and there is no graft-versus-lymphoma (GvL) effect, Consequently, auto-SCT is associated with an increased risk of relapsing disease postprocedure.
read more
Abstract: AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Autologous HSCT (auto-HSCT) enables the application of high-dose chemotherapy (HDT) by subsequent rescue of hematopoiesis by infusion of previously harvested hematopoietic progenitor cells. The most common source of these cells is peripheral blood stem cells mobilized following the use of recombinant growth factors with or without chemotherapy. The toxicity of auto-HSCT continues to fall with improvements in supportive care. Although this approach has a relatively low toxicity compared with allogeneic HSCT (allo-HSCT), there is a persistent risk of tumor cells being present within the harvest and there is no graft-versus-lymphoma (GvL) effect. Consequently, auto-SCT is associated with an increased risk of relapsing disease postprocedure.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma.
TL;DR: In the 47% of collections that were less than optimal, increased resource consumption included increased use of growth factors and antibiotics, subsequent chemotherapy mobilization, increased transfusional support, more apheresis procedures, and more frequent hospitalization.
85
Myeloablative Doses of Yttrium-90- Ibritumomab Tiuxetan and the Risk of Secondary Myelodysplasia/Acute Myelogenous Leukemia
Anna Guidetti,Carmelo Carlo-Stella,Marco Ruella,Rosalba Miceli,L. Devizzi,Silvia L. Locatelli,Arianna Giacomini,Adele Testi,Stefano Buttiglieri,Alessandra Risso,Luigi Mariani,Massimo Di Nicola,Roberto Passera,Corrado Tarella,Alessandro M. Gianni +14 more
TL;DR: The authors evaluated the hematopoietic damage and incidence of secondary myelodysplastic syndrome and acute myelogenous leukemia in patients who received myeloablative doses of the radiolabeled antibody yttrium‐90 (90Y)‐ibritumomab tiuxetan.
References
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
Bertrand Coiffier,Eric Lepage,Josette Brière,Raoul Herbrecht,Hervé Tilly,Reda Bouabdallah,Pierre Morel,Eric Van Den Neste,Gilles Salles,Philippe Gaulard,Felix Reyes,Pierre Lederlin,Christian Gisselbrecht +12 more
TL;DR: A randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma found the rate of complete response was significantly higher in the group that received CHOP plus r ituximabs than in thegroup that receivedCHOP alone.
5.4K
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
Thierry Philip,Cesare Guglielmi,Anton Hagenbeek,Riet Somers,H. Van der Lelie,Dominique Bron,Pieter Sonneveld,Christian Gisselbrecht,Jean-Yves Cahn,Jean Luc Harousseau +9 more
TL;DR: Treatment with high-dose chemotherapy and autologous bone marrow transplantation increases event-free and overall survival in patients with chemotherapy-sensitive non-Hodgkin's lymphoma in relapse.
2.5K
Follicular lymphoma international prognostic index.
Philippe Solal-Celigny,Pascal Roy,Philippe Colombat,J. M. White,James Olen Armitage,Reyes Arranz-Saez,Wing Yan Au,Monica Bellei,Pauline Brice,Dolores Caballero,Bertrand Coiffier,Eulogio Conde-Garcia,Chantal Doyen,Massimo Federico,Richard I. Fisher,Javier García-Conde,Cesare Guglielmi,Anton Hagenbeek,Corinne Haioun,Michael LeBlanc,Andrew Lister,Armando López-Guillermo,Peter McLaughlin,Noel Milpied,Pierre Morel,Nicolas Mounier,Stephen J. Proctor,Ama Z. S. Rohatiner,Paul Smith,Pierre Soubeyran,Hervé Tilly,Umberto Vitolo,Pier Luigi Zinzani,Emanuele Zucca,Emili Montserrat +34 more
TL;DR: The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide to help provide an optimal treatment option for patients with follicular lymphoma.
1.5K
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Wolfgang Hiddemann,Michael Kneba,Martin Dreyling,Norbert Schmitz,Eva Lengfelder,Rudolf Schmits,Marcel Reiser,Bernd Metzner,Harriet Harder,Susanna Hegewisch-Becker,Thomas M. Fischer,Martin Kropff,Hans-Edgar Reis,Mathias Freund,Bernhard Wörmann,Roland Fuchs,Manfred Planker,Jörg Schimke,Hartmut Eimermacher,Lorenz Trümper,Ali Aldaoud,Reza Parwaresch,Michael Unterhalt +22 more
TL;DR: Adding rituximab to CHOP significantly improves the outcome for patients with previously untreated advanced-stage FL and does not induce major adverse effects.
1.3K
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
Anthony H. Goldstone,Susan M. Richards,H M Lazarus,Martin S. Tallman,Georgina Buck,Adele K. Fielding,Alan Kenneth Burnett,R Chopra,Peter H. Wiernik,Letizia Foroni,Elizabeth Paietta,Mark R. Litzow,David I. Marks,Jill Durrant,Andrew McMillan,Ian M. Franklin,Selina M. Luger,Niculae Ciobanu,Jacob M. Rowe +18 more
TL;DR: Matched related allogeneic transplantations for ALL in first complete remission provide the most potent antileukemic therapy and considerable survival benefit for standard-risk patients, but the transplantation-related mortality for high-risk older patients was unacceptably high and abrogated the reduction in relapse risk.
796